AstraZeneca Says $39 Billion Alexion Deal Set for Completion After UK Clearance -- Update
July 14 2021 - 5:11AM
Dow Jones News
By Adria Calatayud
AstraZeneca PLC said Wednesday that its $39 billion acquisition
of Alexion Pharmaceuticals Inc. is expected to close next week
after it obtained final clearance from the U.K. Competition and
Markets Authority
The antitrust watchdog earlier said it has decided not to refer
the deal for an in-depth review based on the information currently
available to it.
AstraZeneca said the acquisition is expected to close on July
21. It previously said the deal was expected to close in the third
quarter.
The company said it will provide updated 2021 financial guidance
for the combined entity in due course.
Earlier this month, the Cambridge, U.K.-based pharmaceutical
company said it had received clearance from the European Union for
its purchase of Alexion.
AstraZeneca in December agreed to acquire Boston-based Alexion
for $39 billion in cash and stock to expand its offering of
treatments for rare diseases.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
July 14, 2021 05:03 ET (09:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
